Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
Go back to Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.48 +0.02 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.46 | 52 Week High | $0.04 | |||
| Open | $4.46 | 52 Week Low | $0.00 | |||
| Day High | $4.52 | P/E | N/A | |||
| Day Low | $4.42 | EPS | $-0.09 | |||
| Volume | 1,077,860 | |||||
